Sarepta Therapeutics Inc (SRPT) concluded trading on Wednesday at a closing price of $18.38, with 10.44 million shares of worth about $191.83 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -84.48% during that period and on July 16, 2025 the price saw a gain of about 0.93%. Currently the company’s common shares owned by public are about 98.25M shares, out of which, 93.47M shares are available for trading.
Stock saw a price change of -5.11% in past 5 days and over the past one month there was a price change of -49.20%. Year-to-date (YTD), SRPT shares are showing a performance of -87.92% which decreased to -84.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $16.88 but also hit the highest price of $153.30 during that period. The average intraday trading volume for Sarepta Therapeutics Inc shares is 5.43 million. The stock is currently trading -1.20% below its 20-day simple moving average (SMA20), while that difference is down -39.85% for SMA50 and it goes to -78.85% lower than SMA200.
Sarepta Therapeutics Inc (NASDAQ: SRPT) currently have 98.25M outstanding shares and institutions hold larger chunk of about 90.23% of that.
The stock has a current market capitalization of $1.81B and its 3Y-monthly beta is at 0.45. It has posted earnings per share of -$2.58 in the same period. It has Quick Ratio of 2.46 while making debt-to-equity ratio of 1.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SRPT, volatility over the week remained 6.44% while standing at 7.05% over the month.
Stock’s fiscal year EPS is expected to drop by -274.25% while it is estimated to increase by 160.92% in next year.
Coverage by TD Cowen stated Sarepta Therapeutics Inc (SRPT) stock as a Hold in their note to investors on June 18, 2025, suggesting a price target of $24 for the stock. On June 17, 2025, Wolfe Research Initiated their recommendations, while on June 16, 2025, Piper Sandler Downgrade their ratings for the stock with a price target of $36. Stock get an Equal-weight rating from Morgan Stanley on June 16, 2025.
